On May 20, 2021 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) reported that new analyses and updates on the ongoing studies of savolitinib, surufatinib, fruquintinib and HMPL-306 will be presented at the upcoming ASCO (Free ASCO Whitepaper)21 Virtual Scientific Program, taking place on June 4-8, 2021 (Press release, Hutchison China MediTech, MAY 20, 2021, View Source [SID1234580343]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aspects of these clinical data disclosures, alongside its PD-1/L1 combination study strategy and corporate update will be discussed part of the previously announced call. For more details, please visit: View Source
SAVOLITINIB
Title:
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer
Lead Author:
Cristina Suárez, MD, Hospital Univ. Vall D Hebron General
Session:
Poster Discussion Session: Genitourinary Cancer—Kidney and Bladder
Abstract Number:
4511
SURUFATINIB
Title:
Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).
Lead Author
Scott Paulson, MD, Baylor Sammons Cancer Center
Session:
Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract Number:
4114
Title:
Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: results from a multicenter, open-label, single-arm, phase II trial
Lead Author
Lin Shen, MD, Peking University Cancer Hospital & Institute
Session:
Online publication only
Number:
e16199
Title:
Phase II trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma
Lead Author
Lin Shen, MD, Peking University Cancer Hospital & Institute
Session:
Online publication only
Number:
e16040
Title:
A single-arm, multi-center, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
Lead Author
Yuxian Bai, MD, PhD, Harbin Medical University Cancer Hospital
Session:
Online publication only
Number:
e16123
Title:
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p)
Lead Author
Xianjun Yu, MD, Fudan University Shanghai Cancer Center
Session:
Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract Number:
4111
Title:
An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors
Lead Author
Arvind Dasari, MD, MS, MD Anderson Cancer Center
Session:
Poster Session: Developmental Therapeutics—Immunotherapy
Abstract Number:
TPS2677
FRUQUINTINIB
Title:
Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer
Lead Author
Ye Guo, MD, Shanghai East Hospital
Session:
Poster Discussion Session: Gastrointestinal Cancer—Colorectal and Anal
Abstract Number:
2514
Title:
A phase Ib trial of assessing the safety and preliminary efficacy of a combination therapy of Geptanolimab (GB 226) plus Fruquintinib in patients with metastatic colorectal cancer (mCRC)
Lead Author
Yanzhi Cui, MD, Tumour Institute, Fourth Hospital of Hebei Medical University
Session:
Online publication only
Number:
e15551
HMPL-306
Title:
A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
Lead Author
Filip Janku, MD, MD Anderson Cancer Center
Session:
Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract Number:
TPS3159
About Savolitinib
Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis. Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile.
In 2011, HUTCHMED entered into a global licensing and joint development and commercialization agreement with AstraZeneca PLC (LSE/STO/NYSE: AZN) for savolitinib. Savolitinib’s global development plan includes non-small cell lung cancer (NSCLC) and kidney cancer, and additional MET-driven tumors are being explored.
About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor ("VEGFR") and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies, where there may be synergistic anti-tumor effects.
HUTCHMED currently retains all rights to surufatinib worldwide.
About Fruquintinib
Fruquintinib is a highly selective and potent oral inhibitor of VEGFRs -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage. The generally good tolerability in patients to date, along with fruquintinib’s low potential for drug-drug interaction based on preclinical assessment, suggests that it may also be highly suitable for combinations with other anti-cancer therapies.
HUTCHMED retains all rights to fruquintinib outside of China. In China, HUTCHMED is partnered with Eli Lilly and Company and is responsible for development and execution of all on-the-ground medical detailing, promotion and local and regional marketing.
About HMPL-306
HMPL-306 is HUTCHMED’s ninth innovative oncology drug candidate that it has discovered that has entered clinical development and the sixth to enter global clinical development. Cytoplasmic mutant IDH1 and mitochondrial mutant IDH2 have been known to switch to the other form when targeted by an inhibitor of IDH1 mutant alone or IDH2 mutant alone. By targeting both IDH1 and IDH2 mutations, HMPL-306 could potentially provide therapeutic benefits in cancer patients harboring either IDH mutation, and may address acquired resistance to IDH inhibition through isoform switching.
HUTCHMED currently retains all rights to HMPL-306 worldwide.